Compare BridgeBio Pharma Inc (BBIO) vs Nomura Holdings Inc (NMR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Nomura Holdings Inc — how do they compare? BridgeBio Pharma Inc trades at $82.33 (market cap $16.46B), while Nomura Holdings Inc trades at $10.02 (market cap $28.06B). The key difference: Nomura Holdings Inc is the larger of the two by market cap, and Nomura Holdings Inc pays a 3.32% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | NMR | |
|---|---|---|
Market Cap | $16.46B | $28.06B |
Sector | Health | Financials |
52-Week High | $90.17 | $9.75 |
52-Week Low | $44.81 | $6.30 |
Enterprise Value | $18.02B | — |
Dividend Yield | — | 3.32% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $83.08, down 3.27% today, near its 52-week high. The stock shows bullish technical momentum with strong moving averages, while fundamentals reveal rapid revenue growth to $502M in 2025 but persistent losses with a -144.4% net margin. Recent news highlights regulatory approvals for acoramidis and a $1B preferred equity raise to fund launches, driving positive sentiment despite earnings misses.
Outlook remains speculative with high execution risk; analyst consensus is strongly bullish (92% buy) targeting $104.57, but profitability challenges and heavy cash burn require successful pipeline commercialization to justify valuation. Key near-term catalysts include FDA decisions on BBP-418 and encaleret in 2026.
Nomura Holdings (NMR) trades at $9.62, down 0.41% on the day, with a P/E of 13.08 suggesting reasonable valuation. The stock shows bullish technical signals with strong moving average support, though RSI levels indicate overbought conditions. Recent earnings show mixed results with one beat and two misses, but annual revenue grew to $1.66 trillion with a robust 20.49% net margin. The company posted record annual profit of $340.74 billion in 2025, driving positive sentiment around its wholesale and wealth management segments.
Nomura presents a compelling value opportunity with strong profitability metrics and expansion in core businesses, though recent earnings misses and negative operating cash flow pose near-term concerns. The bullish analyst consensus and technical setup support upside potential, but investors should monitor integration costs from recent acquisitions and debt levels that have increased to 26.25% of assets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Nomura Holdings Inc
Nomura is Japan's largest broker, about twice the size of rival Daiwa Securities and roughly three times the size of the securities units of the three megabanks. It is also the largest asset-management company in Japan, with a similar size differential compared with its rivals. Despite its topnotch brand name in retail broking and asset management in Japan, Nomura has struggled to compete effectively in the institutional securities business against larger global rivals. In 2008, Nomura bought European and Asian assets of the failed Lehman Brothers, which led to a sharply higher cost base but did not provide commensurate revenue. Nomura has reduced the scale of these businesses but maintains its ambition to compete globally with the top players.
Read more on NMR →
